USD0.000æéå€ååŒÂ  (ET)
1.93BæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
69.920å§å€
70.830é«å€
885.76Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
52.14äºæ³PER
--çŽè¿12ã¶æé
åœ
2.99%売買å転ç
68.960忥çµå€
64.880å®å€
48.57M売買代é
æå€±é¡æ ªäŸ¡åçç
7.60PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-16.33%ç·è³ç£å©çç
170.87052é±é«å€
1.09åºæ¥é«æ¯ç%
-52.29MçŽå©ç
29.67Mæ ªåŒæ°
-2.66041æ ªåœããå©çïŒEPSïŒ
1.99ããŒã¿å€
-30.42%èªå·±è³æ¬å©çç
32.21052é±å®å€
8.63%æ¯ãå¹
66.71%ç²å©çç
1.93BæäŸ¡ç·é¡
0.03ãªã¹ã¯ãªã¿ãŒã³
4.06%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
GeneDx Holdings Corpã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é¡èã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã«ã¹ã±ã¢ãããã€ã㌠& ãµãŒãã¹æ¥çã§ã®é äœã¯75äž11äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯92.89ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
GeneDx Holdings Corpã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
GeneDx Holdings Corpã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
GeneDx Holdings Corp ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
ææšî
ææš
売ã(2)
äžç«(3)
è²·ã(2)
ç§»åå¹³å
売ã(1)
äžç«(0)
è²·ã(5)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
GeneDx Holdings Corpã®äŒæ¥æ
å ±î
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individualâs nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
äŒæ¥ã³ãŒãWGS
äŒæ¥åGeneDx Holdings Corp
æé«çµå¶è²¬ä»»è
ãCEOãStueland (Katherine A)
ãŠã§ããµã€ãhttps://sema4.com/
æ ªäž»çµ±èšî
ãããã質å
GeneDx Holdings CorpïŒWGSïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îGeneDx Holdings CorpïŒWGSïŒã®çŸåšã®æ ªäŸ¡ã¯65.11ã§ãã
GeneDx Holdings Corpã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îGeneDx Holdings Corpã®ãã£ãã«ãŒã·ã³ãã«ã¯WGSã§ãã
GeneDx Holdings Corpã®52é±é«å€ã¯ãããã§ããïŒ
îGeneDx Holdings Corpã®52é±é«å€ã¯170.87ã§ãã
GeneDx Holdings Corpã®52é±å®å€ã¯ãããã§ããïŒ
îGeneDx Holdings Corpã®52é±å®å€ã¯32.21ã§ãã
GeneDx Holdings Corpã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îGeneDx Holdings Corpã®æäŸ¡ç·é¡ã¯1.93Bã§ãã
GeneDx Holdings Corp (WGS) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãGeneDx Holdings CorpïŒWGSïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯92.89ã§ãã
GeneDx Holdings Corp (WGS) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îGeneDx Holdings CorpïŒWGSïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-0.73ã§ãã